Iraq vs Pakistan: Average cost of drugs for extensively drug-resistant tuberculosis
Iraq
2,000 constant 2022 US$
in 2024
Pakistan
1,923 constant 2022 US$
in 2024
Iraq rank
24th
Pakistan rank
27th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Iraq
- Pakistan
How they compare
Iraq currently reports 2,000 constant 2022 US$ against 1,923 constant 2022 US$ in Pakistan, a difference of 77 constant 2022 US$.
The two have swapped places 3 times across 7 shared years of data; in 2018 it was Pakistan ahead.
Iraq ranks 24th and Pakistan ranks 27th of 56 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Iraq | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 7,453 constant 2022 US$ | 3,453 constant 2022 US$ | Pakistan |
| 2020s | 2,400 constant 2022 US$ | 2,824 constant 2022 US$ | 424 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Iraq or Pakistan?
- Iraq, at 2,000 constant 2022 US$ against 1,923 constant 2022 US$ in Pakistan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Iraq and Pakistan?
- 77 constant 2022 US$, with Iraq ahead.
- How many years of comparable data are there for Iraq and Pakistan?
- 7 years are reported by both, from 2018 to 2024.
- How do Iraq and Pakistan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Iraq ranks 24th and Pakistan ranks 27th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.